Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2013 > Volume 22 Number 6 November 2013 > DEVICE EVALUATION > Short-Term Follow Up with the 3f Enable Aortic Bioprosthesis: Clinical and Echocardiographic Results

Short-Term Follow Up with the 3f Enable Aortic Bioprosthesis: Clinical and Echocardiographic Results

Giovanni Concistrè, Antonio Miceli, Federica Marchi, Pierandrea Farneti, Francesca Chiaramonti, Marco Solinas, Alfredo Giuseppe Cerillo Mattia Glauber

Department of Adult Cardiac Surgery, G. Pasquinucci Heart Hospital, Fondazione CNR-G. Monasterio, Massa, Italy

Background and aim of the study: High-risk patients referred for aortic valve replacement (AVR) may benefit from sutureless technology in order to reduce mortality and morbidity. Herein is described the authors’ initial experience and short-term results of the sutureless 3f Enable aortic bioprosthesis.

Methods: A total of 28 patients (19 females, nine males; mean age 76.8 ± 5.1 years; range: 66 to 86 years) with symptomatic aortic valve disease underwent AVR with the 3f Enable bioprosthesis between May 2010 and May 2011. Preoperatively, the mean logistic EuroSCORE was 13.7 ± 10.8%. Concomitant procedures included mitral valve replacement (n = 1), tricuspid valve repair (n = 3) and coronary artery bypass grafting (n = 5). Echocardiography was performed preoperatively, at postoperative day 1, at discharge, and at follow up.

Results: The in-hospital mortality was 3.5% (1/28).


Seventeen patients underwent minimally invasive AVR via an upper partial ministernotomy (n = 13) or a right anterior minithoracotomy (n = 4) approach. The cardiopulmonary bypass (CPB) and aortic crossclamp (ACC) times were 99.4 ± 22.9 and 65.9 ± 18.0 min, respectively, for isolated AVR, and 138.8 ± 62.2 and 100.5 ± 52.2 min, respectively, for combined procedures. One patient underwent aortic root replacement for an intimal aortic lesion after sutureless implantation. At a median follow up of four months (range: 2-10 months), survival was 96.5%, freedom from reoperation was 96.5%, and the mean transvalvular pressure gradient was 11.1 ± 5.4 mmHg.

Conclusion: AVR with the 3f Enable bioprosthesis in high-risk patients is a safe and feasible procedure that is associated with a low mortality and excellent hemodynamic performance.

The Journal of Heart Valve Disease 2013;22:817-823

Short-Term Follow Up with the 3f Enable Aortic Bioprosthesis: Clinical and Echocardiographic Results

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.